캐프리코어 테라퓨틱스(CAPR)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $9.10 (-3.40%), 시가총액 $1.67B, 52주 최저~최고 $4.60 ~ $35.34.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages
캐프리코어 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
캐프리코어 테라퓨틱스의 현재 주가는 $9.10 (-3.40%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
캐프리코어 테라퓨틱스의 시가총액은 약 $1.67B입니다.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and